NURLF (Neural Therapeutics) YoY EPS Growth: -100.00% (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Neural Therapeutics YoY EPS Growth?

Neural Therapeutics NURLF YoY EPS Growth is -100.00% as of Jan. 2026. The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Neural Therapeutics's YoY EPS Growth for the quarter that ended in Jan. 2026 was -100.00%.

Neural Therapeutics's Earnings per Share (Diluted) for the three months ended in Jan. 2026 was $-0.00.

Neural Therapeutics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Neural Therapeutics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neural Therapeutics YoY EPS Growth Chart

Neural Therapeutics Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24 Jul25
YoY EPS Growth
Get a 7-Day Free Trial -150.00 -360.00 43.48 46.15 0.00

Neural Therapeutics Quarterly Data
Jul20 Jul21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 0.00 150.00 100.00 -100.00

Neural Therapeutics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Neural Therapeutics's YoY EPS Growth for the fiscal year that ended in Jul. 2025 is calculated as:

YoY EPS Growth (A: Jul. 2025 )
=(Earnings per Share (Diluted) (A: Jul. 2025 )-Earnings per Share (Diluted) (A: Jul. 2024 ))/ | Earnings per Share (Diluted) (A: Jul. 2024 ) |
=(-0.007--0.007)/ | -0.007 |
=0.00 %

Neural Therapeutics's YoY EPS Growth for the quarter that ended in Jan. 2026 is calculated as:

YoY EPS Growth (Q: Jan. 2026 )
=(Earnings per Share (Diluted) (Q: Jan. 2026 )-Earnings per Share (Diluted) (Q: Jan. 2025 )) / | Earnings per Share (Diluted) (Q: Jan. 2025 )) |
=(-0.002--0.001)/ | -0.001 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -100.00% mean?
Neural Therapeutics (NURLF) has a YoY EPS Growth of -100.00% as of Jan. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Neural Therapeutics and its competitors.
Is Neural Therapeutics' YoY EPS Growth too high?
Neural Therapeutics' current YoY EPS Growth is -100.00%.
How does Neural Therapeutics' YoY EPS Growth compare to VRTX and REGN?
Neural Therapeutics' YoY EPS Growth of -100.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Neural Therapeutics and its competitors. Neural Therapeutics's current YoY EPS Growth is -100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neural Therapeutics stock overvalued right now?
Neural Therapeutics (NURLF) has a current YoY EPS Growth of -100.00%. The current YoY EPS Growth is -100.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Neural Therapeutics (NURLF), the current YoY EPS Growth is -100.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neural Therapeutics Business Description

Other Exchanges M6B:GermanyNURL:Canada
Address 1-130 Adelaide Street West, Suite 3002, Toronto, ON, CAN, M5H 3P5
Neural Therapeutics Inc is a wholly-owned subsidiary of High Fusion focused on ethnobotanical drug discovery and development company. Neural Therapeutics is focused on developing products and conducting research on the psychoactive cacti plants with the primary objective to find where the historical use in traditional medicine proves to be effective and capitalizing on the opportunities that can be applied in modern medical and natural health products markets.